KRAS, BRAF oncogene mutations and tissue specific promoter hypermethylation of tumor suppressor SFRP2, DAPK1, MGMT, HIC1 and p16 genes in colorectal cancer patients

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Cancer Biomarkers

• Publication date

  2016-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3233/CBM-160624PMID 27540971
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Colorectal cancer statistics, 2014

  2014cited by this paper
• The DAPK family: a structure–function analysis

  2014cited by this paper
• Variation risks of SFRP2 hypermethylation between precancerous disease and colorectal cancer

  2014cited by this paper
• Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer

  2012cited by this paper
• Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers

  2012cited by this paper
• BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

  2011cited by this paper
• Systematic Review: Anti–Epidermal Growth Factor Receptor Treatment Effect Modification by KRAS Mutations in Advanced Colorectal Cancer

  2011cited by this paper
• Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.

  2011cited by this paper
• KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer.

  2011cited by this paper
• Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.

  2010cited by this paper
• DNA Sequence Profiles of the Colorectal Cancer Critical Gene Set KRAS-BRAF-PIK3CA-PTEN-TP53 Related to Age at Disease Onset

  2010cited by this paper
• Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours – implications for personalised cancer medicine

  2010cited by this paper
• Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer.

  2010cited by this paper
• KRAS Mutation Correlates With Accelerated Metastatic Progression in Patients With Colorectal Liver Metastases

  2010cited by this paper
• Activating KRAS Mutations and Overexpression of Epidermal Growth Factor Receptor as Independent Predictors in Metastatic Colorectal Cancer Patients Treated With Cetuximab

  2010cited by this paper
• Oncogenetic tree model of somatic mutations and DNA methylation in colon tumors

  2009cited by this paper
• KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.

  2009cited by this paper
• KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803

  2009cited by this paper
• Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.

  2009cited by this paper
• MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events.

  2009cited by this paper
• Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer

  2009cited by this paper
• ASCO Provisional Clinical Opinion: KRAS, Cetuximab, and Panitumumab-Clinical Implications in Colorectal Cancer.

  2009cited by this paper
• MGMT methylation is associated primarily with the germline C>T SNP (rs16906252) in colorectal cancer and normal colonic mucosa

  2009cited by this paper
• Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

  2008cited by this paper
• Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening.

  2008cited by this paper
• TUMORAL TISSUE SPECIFIC PROMOTER HYPERMETHYLATION OF DISTINCT TUMOR SUPPRESSOR GENES IN A CASE WITH NONSMALL CELL LUNG CARCINOMA: A CASE REPORT

  2008cited by this paper
• Comprehensive Biostatistical Analysis of CpG Island Methylator Phenotype in Colorectal Cancer Using a Large Population-Based Sample

  2008cited by this paper
• Hypermethylation of SFRP2 as a Potential Marker for Stool-Based Detection of Colorectal Cancer and Precancerous Lesions

  2007cited by this paper
• Relationship between genetic alterations and prognosis in sporadic colorectal cancer

  2006cited by this paper
• Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis

  2006cited by this paper
• Prognostic value of p16INK4a and p14ARF gene hypermethylation in human colon cancer.

  2006cited by this paper
• DNA hypermethylation in the normal colonic mucosa of patients with colorectal cancer

  2006cited by this paper
• Frequency and spectrum of K-RAS codons 12 and 13 mutations in colorectal adenocarcinomas from Taiwan.

  2005cited by this paper
• Progressive methylation during the serrated neoplasia pathway of the colorectum

  2005cited by this paper
• The tumor suppressor DAP kinase is a target of RSK-mediated survival signaling.

  2005cited by this paper
• Tumour vasculature: On the verge of collapse

  2005cited by this paper
• Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer

  2004cited by this paper
• BRAF Mutation Is Frequently Present in Sporadic Colorectal Cancer with Methylated hMLH1, But Not in Hereditary Nonpolyposis Colorectal Cancer

  2004cited by this paper
• K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study.

  2003cited by this paper
• Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers.

  2003cited by this paper
• Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status

  2002cited by this paper
• Blocking oncogenic Ras signaling for cancer therapy.

  2001cited by this paper
• Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study

  2001cited by this paper
• Expression of the hypermethylated in cancer gene (HIC-1) is associated with good outcome in human breast cancer

  2001cited by this paper
• Methylation of the hMLH1, p16, and MDR1 genes in colorectal carcinoma: associations with clinicopathological features.

  2001cited by this paper
• Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis.

  2000cited by this paper
• Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study.

  2000cited by this paper
• Aging, DNA methylation and cancer.

  1999cited by this paper
• Association of K-ras mutations with p16 methylation in human colon cancer.

  1999cited by this paper
• Heterogeneity of mutant versus wild‐type Ki‐ras in primary and metastatic colorectal carcinomas, and association of codon‐12 valine with early mortality

  1998cited by this paper
• Role of the p16 tumor suppressor gene in cancer.

  1998cited by this paper
• Association between CpG island methylation and microsatellite instability in colorectal cancer.

  1997cited by this paper
• A family of secreted proteins contains homology to the cysteine-rich ligand-binding domain of frizzled receptors.

  1997cited by this paper
• Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway.

  1997cited by this paper
• Type and number of Ki-ras point mutations relate to stage of human colorectal cancer.

  1994cited by this paper

• Multiomics Signature Reveals Network Regulatory Mechanisms in a CRC Continuum

  2025cites this paper
• The Potential of a Cell-Free DNA Methylation-Based Blood Test in Colorectal Cancer Screening

  2025influential citation
• Identification of epigenetic silencing of the SFRP2 gene in colorectal cancer as a clinical biomarker and molecular significance

  2024cites this paper
• BRAF mutations and the association of V600E with CD133 and CDX2 expression in a Pakistani colorectal carcinoma cohort

  2024cites this paper
• Mechanism of DAPK1 for Regulating Cancer Stem Cells in Thyroid Cancer

  2024cites this paper
• Microbiome Dysbiosis, Dietary Intake and Lifestyle-Associated Factors Involve in Epigenetic Modulations in Colorectal Cancer: A Narrative Review

  2024cites this paper
• Microbiota composition and its impact on DNA methylation in colorectal cancer

  2023cites this paper
• MGMT Methylation Is Associated with Human Papillomavirus Infection in Cervical Dysplasia: A Longitudinal Study

  2023cites this paper
• KRAS/NRAS Mutations Associated with Distant Metastasis and BRAF/PIK3CA Mutations Associated with Poor Tumor Differentiation in Colorectal Cancer

  2023cites this paper
• Genome-wide RNA-sequencing dataset reveals AC096751.1 sever as a novel prognostic long non-coding RNA and its potential molecular mechanisms in patients with colon adenocarcinoma

  2023cites this paper
• Diagnostic value of human fecal SDC2 gene in colorectal cancer.

  2023cites this paper
• The Role of Autophagy in Tumor Immune Infiltration in Colorectal Cancer

  2022cites this paper
• Tumor profiling of KRAS, BRAF, and NRAS gene mutations in patients with colorectal cancer: A Lebanese major center cohort study.

  2022cites this paper
• Colorectal Cancer: The Contribution of CXCL12 and Its Receptors CXCR4 and CXCR7

  2022cites this paper
• The promoter methylation drives down-regulation mode of HIC1 in gastric cancer, its molecular characteristics and downstream functional pathways.

  2022cites this paper
• Crosstalk Between DNA Methylation and Gene Mutations in Colorectal Cancer

  2021cites this paper
• Value of methylation markers in colorectal cancer (Review).

  2021influential citation
• Association between HIC1 promoter methylation and solid tumor: A meta-analysis

  2020cites this paper
• Opposite Roles of the JMJD1A Interaction Partners MDFI and MDFIC in Colorectal Cancer

  2020cites this paper
• Association between SFRP promoter hypermethylation and different types of cancer: A systematic review and meta-analysis

  2019cites this paper
• Novel SFRP2 DNA Methylation Profile Following Neoadjuvant Therapy in Colorectal Cancer Patients with Different Grades of BMI

  2019cites this paper
• DNA methylation changes that precede onset of dysplasia in advanced sessile serrated adenomas

  2019cites this paper
• Organochlorine and organophosphorous pesticides may induce colorectal cancer; A case-control study.

  2019cites this paper
• A novel LARCassigner3 classification predicts outcomes in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy: a retrospective training and validation analysis

  2019cites this paper
• Associations of MGMT promoter hypermethylation with squamous intraepithelial lesion and cervical carcinoma: A meta-analysis

  2019cites this paper
• Epigenetic and epitranscriptomic changes in colorectal cancer: Diagnostic, prognostic, and treatment implications.

  2018cites this paper
• A novel discriminating colorectal cancer model for differentiating normal and tumor tissues.

  2018cites this paper
• Promoter methylation and expression of DNA repair genes MGMT and ERCC1 in tissue and blood of rectal cancer patients.

  2018cites this paper
• BCR‐ABL enhances the prolyl isomerase activity of Pin 1 by interacting with DAPK1 in ph+ ALL

  2018cites this paper
• The 9p21 locus as a potential therapeutic target and prognostic marker in colorectal cancer.

  2018cites this paper
• The role of TFPI2 hypermethylation in the detection of gastric and colorectal cancer

  2017cites this paper
• Correlation of DAPK1 methylation and the risk of gastrointestinal cancer: A systematic review and meta-analysis

  2017cites this paper
• EGFR , KRAS and BRAF mutations in Chinese patients with clear cell renal cell carcinoma

  2016cites this paper